Ranked by engagement
Top topics — all time
Ranked by replies, likes and views over all time, with a bonus for topics that reached a marked solution. Engagement is a proxy for usefulness and a poor one; the documentation commons is the better index of what is settled.
1,535 topics · page 1 of 40
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Correlation in a self-tracked dataset: what it can support
Correlation in a self-tracked dataset: what it can support — setting out what I have, and where I think it stops being reliable. Posting a small dataset on correlation. It is mine, it is uncontrolled, and the…
|
+152 | 166 | 48k | 23mo |
|
Are there stupid questions here? A staff answer, at length
Are there stupid questions here? A staff answer, at length I have a specific reason for asking rather than idle curiosity, and the context is below. Question in the title and the context underneath, in the…
|
+122 | 153 | 50k | 11mo |
|
The mass-error checker and its intended scope
The mass-error checker and its intended scope Writing it up because I had to work it out twice and would rather nobody else did. Proposing that mass-error checker deserves a maintained page rather than a…
|
+149 | 167 | 42k | 2y |
|
Journal club: SURMOUNT-1, read without the press release
Journal club: SURMOUNT-1, read without the press release Writing it up because I had to work it out twice and would rather nobody else did. Posting a small dataset on SURMOUNT-1. It is mine, it is…
|
+139 | 157 | 66k | 12mo |
|
A 10 mg vial reconstituted three different ways, compared — the long version
A 10 mg vial reconstituted three different ways, compared — the long version — setting out what I have, and where I think it stops being reliable. Asking about 10 mg vial reconstituted three directly, because…
|
+146 | 158 | 47k | 9mo |
|
Second pass at: A field-by-field walk through a certificate of analysis
Second pass at: A field-by-field walk through a certificate of analysis Writing it up because I had to work it out twice and would rather nobody else did. The question about field-by-field walk through a…
|
+149 | 164 | 36k | 19mo |
|
Validating a method you did not develop — does this still hold?
Validating a method you did not develop — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Validating a method, and specifically the version of…
|
+128 | 148 | 47k | 16mo |
|
Cold packs, phase-change material, and what survives ten days
Cold packs, phase-change material, and what survives ten days — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin cold packs down and I want to set out…
|
+132 | 138 | 65k | 2y |
|
When a preprint is the best available evidence and we say so
When a preprint is the best available evidence and we say so — that is the question, and I have not found it answered plainly anywhere I have looked. A preprint question rather than a question about the…
|
+148 | 160 | 31k | 11mo |
|
Pharmaceutical compounding rules, summarised from primary sources
Pharmaceutical compounding rules, summarised from primary sources — setting out what I have, and where I think it stops being reliable. Asking what a regulator's document actually says, since the summaries of…
|
+135 | 163 | 46k | 17mo |
|
Domestic fridge temperature mapping: a cheap experiment — what changed since
Domestic fridge temperature mapping: a cheap experiment — what changed since — setting out what I have, and where I think it stops being reliable. What changes if the standard account of Domestic fridge…
|
+145 | 155 | 46k | 12mo |
|
Oral semaglutide bioavailability and its variability between people — a second dataset
Oral semaglutide bioavailability and its variability between people — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Oral semaglutide…
|
+141 | 154 | 47k | 19mo |
|
One lot is one lot: when a report becomes a pattern — the long version
One lot is one lot: when a report becomes a pattern — the long version — setting out what I have, and where I think it stops being reliable. Structured report rather than an opinion, following the format the…
|
+137 | 152 | 46k | 16mo |
|
Research-use-only labelling: what it means and what it does not — the long version
Posting this under the heading it deserves: Research-use-only labelling: what it means and what it does not — the long version Everything below is what sits behind that. A labelling question, and I would like…
|
+150 | 158 | 55k | 14mo |
|
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin tirzepatide in type 2…
|
+150 | 163 | 22k | 11mo |
|
Retatrutide dose escalation in the published trials
Posting this under the heading it deserves: Retatrutide dose escalation in the published trials Everything below is what sits behind that. An honest uncertainty about retatrutide dose escalation rather than a…
|
+149 | 159 | 30k | 15mo |
|
Second pass at: Metformin co-administration and additive GI effects
On the subject in the title: Second pass at: Metformin co-administration and additive GI effects Working notes rather than a conclusion. Posting a small dataset on Metformin co-administration. It is mine, it…
|
+131 | 142 | 56k | 19d |
|
Follow-up: Where the four-week escalation interval comes from, and what it is not
Where the four-week escalation interval comes from, and what it is not Writing it up because I had to work it out twice and would rather nobody else did. A follow-up question about four-week escalation…
|
+131 | 147 | 47k | 18mo |
|
Coming back to: Preparing for an appointment: one page, three questions
Posting this under the heading it deserves: Preparing for an appointment: one page, three questions Everything below is what sits behind that. A question about how to describe something to a clinician rather…
|
+139 | 151 | 47k | 18mo |
|
"Greater than or equal to 99%" as a specification rather than a result
"Greater than or equal to 99%" as a specification rather than a result Writing it up because I had to work it out twice and would rather nobody else did. Setting out an integration problem with the actual…
|
+132 | 146 | 47k | 5mo |
|
Amylin analogue mechanism: satiety signalling separate from GLP-1
Amylin analogue mechanism: satiety signalling separate from GLP-1 — setting out what I have, and where I think it stops being reliable. Trying to work out what would count as evidence on amylin analogue…
|
+128 | 142 | 38k | 13mo |
|
The anatomy of a question that gets answered within an hour — the long version
The anatomy of a question that gets answered within an hour — the long version Writing it up because I had to work it out twice and would rather nobody else did. Question in the title. Context below, and I…
|
+129 | 142 | 49k | 8mo |
|
EMA product information as a primary source — does this still hold?
The question in the title: EMA product information as a primary source — does this still hold? I will give what I have already checked below so nobody repeats it. Something about EMA product information does…
|
+127 | 150 | 41k | 20mo |
|
Price changes over 2025 and 2026, tabulated and dated — does this still hold?
Price changes over 2025 and 2026, tabulated and dated — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Documenting an access outcome, dated,…
|
+147 | 156 | 18k | 3mo |
|
When "no data" is the complete and final answer
Asking directly, because I could not find a straight answer: When "no data" is the complete and final answer Asking about the compound itself rather than about a trial of it. I have read the maintained page…
|
+154 | 165 | 6.3k | 15mo |
|
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field — setting out what I have, and where I think it stops being reliable. Collecting what is known about SURMOUNT-OSA in one place,…
|
+108 | 122 | 52k | 7d |
|
Requesting a page: what makes a good request — what changed since
Posting this under the heading it deserves: Requesting a page: what makes a good request — what changed since Everything below is what sits behind that. What changes if the standard account of Requesting a…
|
+126 | 141 | 50k | 21mo |
|
Time to steady state after a dose increase
On the subject in the title: Time to steady state after a dose increase Working notes rather than a conclusion. Working through the kinetics rather than the pharmacology, because I think the confusion here is…
|
+151 | 163 | 9.7k | 21mo |
|
Sleep tracking data and its considerable limitations
Sleep tracking data and its considerable limitations — setting out what I have, and where I think it stops being reliable. A measurement question rather than a physiology one. Consumer sleep trackers report…
|
+109 | 126 | 61k | 9mo |
|
[2026 update] Regional warehouse stock versus direct despatch
Regional warehouse stock versus direct despatch Writing it up because I had to work it out twice and would rather nobody else did. Working notes on Regional warehouse stock versus direct rather than a…
|
+135 | 147 | 32k | 2d |